Janus Face of Drug-Induced Tetraploidy in Non-Hodgkin Lymphoma

Daruka Mahadevan; Gregory C Rogers

doi:10.1016/j.trecan.2020.03.009

Janus Face of Drug-Induced Tetraploidy in Non-Hodgkin Lymphoma

Trends Cancer. 2020 Aug;6(8):627-630. doi: 10.1016/j.trecan.2020.03.009. Epub 2020 Apr 11.

Authors

Daruka Mahadevan¹, Gregory C Rogers²

Affiliations

¹ Division of Hematology/Oncology, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA. Electronic address: mahadevand@uthscsa.edu.
² Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.

PMID: 32291237
DOI: 10.1016/j.trecan.2020.03.009

Abstract

Anticancer agents often cause drug-induced tetraploidy (DIT) in cancer cells. DIT is not only a mechanism of inherited drug resistance, but proliferating DIT cells can produce progeny with increased ploidy or aneuploid genomes that drive aggressive disease. Here, we explore combinatorial therapeutic strategies for either preventing or eliminating DIT cells.

Keywords: aneuploidy; drug resistance; polyploidy; tetraploidy; tumor evolution.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chromosomal Instability / drug effects
Chromosome Segregation / drug effects*
DNA Replication / drug effects
Humans
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / genetics
Tetraploidy*